PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16481390-7	2006	The DNA incorporation of L-OddC, but not that of dFdC, was decreased by the induction of wt APE-1 but not E96A mutant and was increased by the down-regulation of APE-1.	troxacitabine	25-31	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	92-97
16481390-0	2006	Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2",3"-dideoxy-2",3"-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).	troxacitabine	129-142	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-36
16481390-7	2006	The DNA incorporation of L-OddC, but not that of dFdC, was decreased by the induction of wt APE-1 but not E96A mutant and was increased by the down-regulation of APE-1.	troxacitabine	25-31	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	162-167
16481390-2	2006	We showed that human apurinic/apyrimidinic endonuclease (APE-1) has exonuclease activity for preferentially removing L-OddC and other L-configuration nucleosides over D-configuration nucleosides from the 3" terminus of DNA in vitro.	troxacitabine	117-123	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	57-62
16481390-8	2006	The rate of retention of L-OddC was inversely correlated to the level of APE-1 in isolated nuclei; however, this was not the case for dFdC.	troxacitabine	27-31	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	73-78
17065050-6	2006	Catalytically inactive p53 seems to increase the sensitivity to troxacitabine.	troxacitabine	64-77	tumor protein p53	Homo sapiens	23-26
16211462-0	2005	Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer.	troxacitabine	18-31	chimerin 2	Homo sapiens	33-36
17065050-1	2006	Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK).	troxacitabine	0-13	deoxycytidine kinase	Homo sapiens	109-129
17065050-1	2006	Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK).	troxacitabine	0-13	sticky	Drosophila melanogaster	131-134
12697876-0	2003	Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.	troxacitabine	18-31	chimerin 2	Homo sapiens	33-36
15266019-8	2004	One explanation that emerged from enzyme assays of deoxycytidine kinase (dCK) and deoxycytidine monophosphate kinase (dCMPK), key enzymes involved in L-OddC phosphorylation, was that CPT protected against L-OddC-induced reduction in dCK and dCMPK activity.	troxacitabine	150-156	deoxycytidine kinase	Homo sapiens	51-71
15266019-8	2004	One explanation that emerged from enzyme assays of deoxycytidine kinase (dCK) and deoxycytidine monophosphate kinase (dCMPK), key enzymes involved in L-OddC phosphorylation, was that CPT protected against L-OddC-induced reduction in dCK and dCMPK activity.	troxacitabine	150-156	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	73-76
15069761-0	2004	Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.	troxacitabine	10-23	cytidine deaminase	Homo sapiens	55-73
15069761-3	2004	In contrast to other cytosine nucleoside analogs, troxacitabine is resistant to inactivation by cytidine deaminase (CD).	troxacitabine	50-63	cytidine deaminase	Homo sapiens	96-114
15069761-3	2004	In contrast to other cytosine nucleoside analogs, troxacitabine is resistant to inactivation by cytidine deaminase (CD).	troxacitabine	50-63	cytidine deaminase	Homo sapiens	116-118
15069761-4	2004	In this study we have investigated the effects of increased intracellular levels of CD on the antineoplastic action of troxacitabine and the related antileukemic drug, cytosine arabinoside (ARA-C).	troxacitabine	119-132	cytidine deaminase	Homo sapiens	84-86
15069761-7	2004	In contrast, the CD-transduced cells were as or more sensitive to the cytotoxic action of troxacitabine than the wild type cells.	troxacitabine	90-103	cytidine deaminase	Homo sapiens	17-19
15069761-8	2004	These results suggest that troxacitabine may be an effective antineoplastic agent against tumors with high levels of CD that show drug resistance to cytosine nucleoside analogs.	troxacitabine	27-40	cytidine deaminase	Homo sapiens	117-119
12624104-5	2003	APE1 showed a similar K(m) value for matched, 3" mispaired, or nucleoside analog beta-l-dioxolane-cytidine terminated nicked DNA as well as for DNA containing a tetrahydrofuran, an abasic site analog.	troxacitabine	81-106	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	0-4
12697876-1	2003	PURPOSE: A multi-institution phase II study was undertaken by National Cancer Institute of Canada-Clinical Trials Group to evaluate the efficacy and toxicity of intravenous troxacitabine (Troxatyl; Shire Pharmaceuticals Plc, Laval, Quebec, Canada), in patients with renal cell carcinoma.	troxacitabine	173-186	heparan sulfate proteoglycan 2	Homo sapiens	220-223
12011137-1	2002	PURPOSE: Troxacitabine (Troxatyl, BCH-4556; BioChem Pharma Inc, Basingstoke, United Kingdom) is a novel synthetic L-nucleoside analog with activity against a broad range of human tumors in preclinical models.	troxacitabine	9-22	chimerin 2	Homo sapiens	34-37
12848594-0	2003	Troxacitabine: BCH 4556, SPD 758, Troxatyl.	troxacitabine	0-13	chimerin 2	Homo sapiens	15-18
12848594-1	2003	Troxacitabine [BCH 4556; SPD 758; Troxatyl] is a DNA synthesis inhibitor.	troxacitabine	0-13	chimerin 2	Homo sapiens	15-18
12451476-3	2002	This unusual property led us to evaluate the efficacy of troxacitabine in multidrug resistant (MDR) and multidrug resistance-associated protein (MRP) tumors.	troxacitabine	57-70	ATP binding cassette subfamily C member 3	Homo sapiens	104-143
12451476-3	2002	This unusual property led us to evaluate the efficacy of troxacitabine in multidrug resistant (MDR) and multidrug resistance-associated protein (MRP) tumors.	troxacitabine	57-70	ATP binding cassette subfamily C member 3	Homo sapiens	145-148
11320667-1	2001	PURPOSE: Troxacitabine (beta-L-dioxolane cytidine, BCH-4556; Troxatyl, BioChem Pharma Inc.) is a novel nucleoside analogue, which in experiments demonstrated potent antitumor activity against both leukemias and solid tumors.	troxacitabine	9-22	chimerin 2	Homo sapiens	51-54
11585758-3	2001	The CCRF-CEM leukemia cell line was highly sensitive to the antiproliferative effects of troxacitabine, gemcitabine, and cytarabine with inhibition of proliferation by 50% observed at 160, 20, and 10 nM, respectively, whereas a deoxycytidine kinase (dCK)-deficient variant (CEM/dCK(-)) was resistant to all three drugs.	troxacitabine	89-102	deoxycytidine kinase	Homo sapiens	228-248
11585758-3	2001	The CCRF-CEM leukemia cell line was highly sensitive to the antiproliferative effects of troxacitabine, gemcitabine, and cytarabine with inhibition of proliferation by 50% observed at 160, 20, and 10 nM, respectively, whereas a deoxycytidine kinase (dCK)-deficient variant (CEM/dCK(-)) was resistant to all three drugs.	troxacitabine	89-102	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	250-253
11585758-3	2001	The CCRF-CEM leukemia cell line was highly sensitive to the antiproliferative effects of troxacitabine, gemcitabine, and cytarabine with inhibition of proliferation by 50% observed at 160, 20, and 10 nM, respectively, whereas a deoxycytidine kinase (dCK)-deficient variant (CEM/dCK(-)) was resistant to all three drugs.	troxacitabine	89-102	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	278-281
11585758-5	2001	Analysis of troxacitabine transportability by the five molecularly characterized human nucleoside transporters [human equilibrative nucleoside transporters 1 and 2, human concentrative nucleoside transporter (hCNT) 1, hCNT2, and hCNT3] revealed that short- and long-term uptake of 10-30 microM [(3)H]troxacitabine was low and unaffected by the presence of either nucleoside transport inhibitors or high concentrations of nonradioactive troxacitabine.	troxacitabine	12-25	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	118-163
11585758-5	2001	Analysis of troxacitabine transportability by the five molecularly characterized human nucleoside transporters [human equilibrative nucleoside transporters 1 and 2, human concentrative nucleoside transporter (hCNT) 1, hCNT2, and hCNT3] revealed that short- and long-term uptake of 10-30 microM [(3)H]troxacitabine was low and unaffected by the presence of either nucleoside transport inhibitors or high concentrations of nonradioactive troxacitabine.	troxacitabine	12-25	solute carrier family 28 member 1	Homo sapiens	171-216
11585758-9	2001	Sequence analysis of cDNAs encoding dCK revealed a mutation of a highly conserved amino acid (Trp(92)-->Leu) in DU145(R) dCK, providing a possible explanation for the reduced phosphorylation of troxacitabine in DU145(R) lysates.	troxacitabine	197-210	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	36-39
11320667-15	2001	CONCLUSIONS: Our findings indicate that troxacitabine is likely to be effective not only against solid tumors with high CDA activity but also in leukemias which have developed resistance to AraC due to increased CDA levels; this suggests that troxacitabine is a promising agent for the treatment of cancer.	troxacitabine	40-53	cytidine deaminase	Homo sapiens	120-123
11320667-15	2001	CONCLUSIONS: Our findings indicate that troxacitabine is likely to be effective not only against solid tumors with high CDA activity but also in leukemias which have developed resistance to AraC due to increased CDA levels; this suggests that troxacitabine is a promising agent for the treatment of cancer.	troxacitabine	40-53	cytidine deaminase	Homo sapiens	212-215
10906132-9	2000	This discovery suggests that APE1 could be critical for the activity of l-OddC or other l-nucleoside analogs and may play additional important roles in cells that were not previously known.	troxacitabine	72-78	apurinic/apyrimidinic endodeoxyribonuclease 1	Homo sapiens	29-33
9354442-0	1997	Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.	troxacitabine	68-93	chimerin 2	Homo sapiens	58-61
10778991-0	2000	The new dioxolane, (-)-2"-deoxy-3"-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.	troxacitabine	58-71	chimerin 2	Homo sapiens	48-51
9354442-1	1997	Beta-L-Dioxolane-cytidine (BCH-4556) is a novel anticancer nucleoside analogue with a stereochemically unnatural beta-L configuration.	troxacitabine	0-25	chimerin 2	Homo sapiens	27-30
34336378-24	2021	In patients with trauma to the hip joint or hip interventions, the swelling at the femur was reduced by 8.6% between LTT 0 vs. 4.	troxacitabine	117-120	hedgehog interacting protein	Homo sapiens	44-47
24731063-6	2014	In addition, LTT- and calcium-treated groups also presented decreased levels of TNF-alpha in periodontal tissues and increased levels of calcium in serum.	troxacitabine	13-16	tumor necrosis factor	Mus musculus	80-89
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 4	Homo sapiens	18-22
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 4	Homo sapiens	24-29
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 5	Homo sapiens	35-39
25674464-0	2014	Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.	troxacitabine	107-120	ATP binding cassette subfamily C member 5	Homo sapiens	41-46
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 4	Homo sapiens	76-80
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 4	Homo sapiens	82-87
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 5	Homo sapiens	93-97
25674464-1	2014	UNLABELLED: We aimed to determine whether the multidrug-resistance-proteins MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the antimetabolites cytarabine (Ara-C), gemcitabine (GEM), and the L-nucleoside analog troxacitabine.	troxacitabine	214-227	ATP binding cassette subfamily C member 5	Homo sapiens	99-104
25674464-4	2014	At 4-hr exposure HEK/MRP4 cells were 2-4-fold resistant to troxacitabine, ara-C and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), and HEK/MRP5i to ara-C and PMEA, but none to GEM.	troxacitabine	59-72	ATP binding cassette subfamily C member 4	Homo sapiens	21-25
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine	65-78	ATP binding cassette subfamily C member 4	Homo sapiens	15-19
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine	65-78	ATP binding cassette subfamily C member 5	Homo sapiens	24-28
25674464-10	2014	IN CONCLUSION: MRP4 and MRP5 overexpression confer resistance to troxacitabine and ara-C, but not to GEM, which was associated with a rapid decline of the ara-C and troxacitabine-nucleotides in HEK/MRP4-5 cells.	troxacitabine	65-78	ATP binding cassette subfamily C member 4	Homo sapiens	198-202
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	220-233	deoxycytidine kinase	Homo sapiens	50-70
17565005-1	2007	beta-L-Dioxolane-cytidine (L-OddC, Troxacitabine, BCH-4556), a novel L-configuration deoxycytidine analog, is under clinical trials for treating cancer.	troxacitabine	0-25	NK2 homeobox 1	Homo sapiens	50-53
17565005-10	2007	The knockdown of HIF-1alpha in inducible shRNA in RKO cells reduced the cytotoxicity of L-OddC but not dFdC under hypoxic conditions.	troxacitabine	88-94	hypoxia inducible factor 1 subunit alpha	Homo sapiens	17-27
17558697-1	2007	Troxacitabine (Troxatyl; BCH-4556; (-)-2"-deoxy-3"-oxacytadine) is the first synthetic l-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity.	troxacitabine	0-13	chimerin 2	Homo sapiens	25-28
17146106-10	2007	In 27 patients achieving target troxacitabine plasma concentrations (ie, approximately 80 ng/mL) the CR + CRp rate was 26%.	troxacitabine	32-45	C-reactive protein	Homo sapiens	101-103
17158155-0	2007	Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.	troxacitabine	80-93	deoxycytidine kinase	Homo sapiens	103-123
18058539-1	2007	Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK).	troxacitabine	0-13	deoxycytidine kinase	Homo sapiens	109-129
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	220-233	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	72-75
18058539-1	2007	Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK).	troxacitabine	0-13	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	131-134
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	220-233	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	115-121
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	235-238	deoxycytidine kinase	Homo sapiens	50-70
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	235-238	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	72-75
17158155-3	2007	Herein, we report the crystal structures of human deoxycytidine kinase (dCK) in complex with the L-nucleosides (-)-beta-2",3"-dideoxy-3"-thiacytidine (3TC)--an approved anti-human immunodeficiency virus (HIV) agent--and troxacitabine (TRO)--an experimental anti-neoplastic agent.	troxacitabine	235-238	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	115-121
17607581-1	2006	Troxacitabine (Troxatyl; BCH-4556; (-)-2"-deoxy-3"-oxacytadine) is the first synthetic l-nucleoside enantiomer to demonstrate broad spectrum cytotoxic activity.	troxacitabine	0-13	chimerin 2	Homo sapiens	25-28